THE EXPRESSION OF APOPTOSIS RELATED GENES IN THE PROCESS OF CANCERATION OF ATYPICAL HYPERPLASIA OF MAMMARY DUCT

Objective： To investigate the expression of apoptosis related genes p53 and bcl-2 in atypical hyperplasia of mammary duct and the relationship between the gene expression and oncogenesis of breast. Methods： mRNA of apoptosis related gene p53 and bcl-2 were detected by in situ hybridization in 44 cases of atypical ductal hyperplasia. p53 protein expression was detected by immunohistochemistry. The data were compared with those of 6 cases of benign hyperplasia and 26 cases of breast carcinoma. Results： The expression of p53 mRNA was 66.7% in benign hyperplasia, 40% in atypical ductal hyperplasia （55.6% in mild, 41.7% in medium, 26.1% in severe） and 19.2% in carcinoma （of which 21.4% were intraductal carcinoma and 16.7% were invasive）. The expression of p53 protein was negative in benign hyperplasia, 24% in atypical hyperplasia （mild 11.1%, medium 25%, severe 34.8%）, 38.5% in carcinoma （intraductal carcinoma 35.7%, invasive ductal carcinoma 41.7%）. The expression of bcl-2 was negative in benign hyperplasia, 78.6% in intraductal carcinoma, 83.3% in invasive ductal carcinoma. Conclusion： Loss and mutation of p53 gene and excessive expression bcl-2 mRNA were detected in severe atypical ductal hyperplasia.     

In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions.

Forty-four specimens of non-malignant and malignant human lung tissue, taken from patients with non-small cell lung cancer (NSCLC), were examined for the expression of wild-type p53, mutant p53, and bcl-2 and the occurrence of programmed cell death (apoptosis). Wild-type p53 expression peaked in peritumoral and metaplastic samples, whereas mutant p53, bcl-2 and apoptosis were first detected in metaplasia and increased with progression to carcinoma. Bcl-2 positive samples had lower levels of apoptosis than bcl-2 negative samples and was independent of wild-type or mutant p53 expression. These results suggest that the over-expression of wild-type p53 may be an early cellular response to an alteration in normal cellular homeostasis. The ensuing increase in apoptosis appears to be relatively independent of mutant or wild-type p53 expression, but does not occur in cells expressing bcl-2.     

膀胱癌癌旁组织的病理学及p53蛋白、bcl-2表达意义

 目的　探讨膀胱癌癌旁组织的病理学改变和p5 3、bcl 2基因的表达意义。方法　采用免疫组化SP法 ,对 5 8例行手术治疗的膀胱癌标本 ,分别进行 p5 3、bcl 2基因的检测。 结果　p5 3阳性表达在膀胱癌的不同病理分期及分级中具有显著性差异 (P <0 .0 1) ;bcl 2基因阳性表达在浅表性膀胱癌与浸润性膀胱癌具有差异 (P <0 .0 5 ) ,bcl 2基因阳性表达在不同病理分级中具有显著性差异 (P <0 .0 1)。结论　p5 3阳性表达、bcl 2阴性表达的膀胱癌具有恶性程度高、易复发的特点 ;癌旁组织恶变发生率 ,浸润性膀胱癌 5 6 .4 % ,浅表性膀胱癌 2 1.1% ,提示手术时尽可能保证足够的切除范围。     

Expression of Inducible Nitric Oxide Synthase, p53 and Bcl-2 in Gastric Precancerous and Cancerous Lesions： Correlation with Clinical Features

OBJECTIVE To explore the expression of inducible nitric oxide synthase (iNOS), p53 and bcl -2 in gastric precancerous and cancerous lesions and to examine the expression of these proteins in relation to clinical features. METHODS The expressions of iNOS, p53 and bcl-2 proteins in gastric precancerous and cancerous lesions and their correlations with the clinical features were determined using immunohistochemical assays (Power VisionTM two -step method) on 84 gastric carcinomas and 54 gastric atypical hyperplastic tissues. Apoptotic cells were evaluated by terminal deoxynucleotidyl transferase- mediated dUTP-biotin nick-end labeling (TUNEL). RESULTS Expression of iNOS, p53 and bcl-2 was significantly higher in gastric carcinoma (GC) tissues than in gastric atypical hyperplastic tissues. Among the 84 carcinomas, the expression of p53 was observed in 50 (59.52%), bcl-2 in 43 (51.19%), and iNOS in 65 (77.58%). Overex-pression of iNOS and bcl-2 in gastric carcinoma was related to tumor size and iNOS was related to the presence of lymph node metastasis (P< 0.05). The expression of proteins did not correlate with age, sex, stage of disease, or differentiation. Expression of iNOS in gastric carcinoma tissues was positively correlated with bcl-2 expression (X2=8.926, P=0.003), and also with p53 expression (X2= 5.2430, P= 0.022). The mean apoptotic indexes (Al) were 1.29%±0.50 in low-grade atypical hyperplasia (LG), 0.96%±0.36 in high-grade atypical hyperplasia (HG) and 0.70%±0.43 in GC, with the difference being significant between LG, HG and GC (P< 0.05). There was a significant positive correlation between iNOS expression and the Al in GC (t=3.0815, P=0.0028). CONCLUSION iNOS was expressed in the majority of gastric carcinoma tissues and correlated with cellular apoptosis associated with p53 and bcl -2 expression. iNOS overexpression is closely associated with p53 and bcl-2 accumulation status. iNOS may play a synergistic role in the pathogenesis of GC.     

Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer

It has been reported that genes regulating apoptosis may play a role in tumoral angiogenesis. This study examined the relationship between tumour vascularization, a measure of tumour angiogenesis, and bcl-2 and p53 expression in operable non-small-cell lung cancer (NSCLC). The relationship between bcl-2, p53 and tumour vascularization and epidermal-growth-factor-receptor(EGFR) and c-erbB-2 expression was also studied. Tissue sections from resected tumour specimens of 107 NSCLC patients were evaluated immunohistochemically for vascular grade and bcl-2, p53, EGFR and c-erbB-2 expression. bcl-2 expression was found in 20/107 (19%) cases and was associated with squamous-cell histology (p = 0.03). A strong inverse relationship was found between bcl-2 expression and vascular grade (p = 0.005). All c-erbB-2-positive cases were negative for bcl-2 expression (p = 0.01). Overall no association was found between c-erbB-2 expression and vascular grade. However, in bcl-2-negative cases positive c-erbB-2 expression correlated with low angiogenesis (p = 0.05). No relationship was found between p53 and EGFR expression and bcl-2, c-erbB-2 or vascular grade. The improved prognosis reported in bcl-2-positive NSCLC may be related to low tumour vascularization. The results suggest that the anti-apoptotic gene bcl-2 plays a role in regulating tumour angiogenesis. Since normal lung epithelium expresses bcl-2, a sequence of tumour progression involving loss of bcl-2, then activation of c-erbB-2 or increase in tumour vascularization is proposed. Int. J. Cancer 74:565–570, 1997.© 1997 Wiley-Liss, Inc.     

Apoptotic activity is increased in parallel with the metaplasia-dysplasia-carcinoma sequence of the bronchial epithelium

A high level of apoptotic activity and an independence of apoptosis from the expression of p53 and bcl-2 have been observed in non-small-cell lung carcinoma. We examined 44 samples of normal, metaplastic and premalignant (i.e. mild, moderate and severe dysplasias and carcinoma in situ) bronchial epithelia to evaluate whether differences in the apoptotic activity could already be seen in the stages preceding squamous cell carcinoma of the lung (SQCLC). Apoptotic cells and bodies were visualized by 3' end labelling. The expression of p53 and members of the bcl-2 gene family, such as bcl-2, bax and mcl-1, were determined immunohistochemically with specific antibodies. The relative number of apoptotic cells and bodies [apoptotic index (AI%)] was already increased threefold as the normal bronchial epithelium changed to squamous metaplasia, and the AIs of the dysplastic lesions were about four times higher than those of the normal epithelium. Apoptosis was significantly associated with cell proliferation, as determined by proliferating cell nuclear antigen (PCNA) immunohistochemistry. However, the extent of apoptosis did not correlate with the expression of p53, bcl-2, bax and mcl-1. We conclude that, in the metaplasia-dysplasia-carcinoma sequence in the lung, the elevation of the AI% is an early event associated with cell proliferation activity, but is independent of the expression of p53, bcl-2, mcl-1 and bax.     

Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer

BACKGROUND: Tumor staging remains the most important prognostic predictor in patients with non-small cell lung cancer (NSCLC). However, the prognostic significance of expression of oncoproteins involved in regulation of cellular uncontrolled proliferation remains controversial. METHODS: In this retrospective study, we investigated the expression of bcl-2 and p53 oncoproteins in 114 surgically resected NSCLC patients (46 stage I, 39 stage II and 29 stage IIIa) using immunohistochemical analysis and correlated the molecular markers with survival. RESULTS: Positive bcl-2 immunoreactivity was detected in 26 of 114 (22.8%) NSCLC, including 15 of 43 (34.9%) squamous cell carcinoma and 11 of 71 (15.5%) adenocarcinoma cases. Nuclear staining for p53 was observed in 59 of 114 (51.8%) NSCLC, including 26 of 43 (60.5%) squamous cell carcinoma and 33 of 71 (46.5%) adenocarcinoma patients. There was no correlation between pathological staging and expression of bcl-2 and p53. However, the expression frequency of bcl-2 was significantly higher in squamous cell carcinoma than in adenocarcinoma (P < 0.02). The presence of bcl-2 expression did not provide a favorable prognosis (P = 0.23) and the overexpression of p53 oncoprotein was also not significantly associated with adverse prognosis (P = 0.09). No inverse relationship was found between bcl-2 and p53 expression (P = 0.83). CONCLUSION: Expressions of bcl-2 and p53 using immunohistochemical staining are not independent prognostic predictors in patients undergoing surgery for NSCLC.     

Immunohistochemical analysis of bcl-2 and p53 protein in breast carcinoma

We analyzed the expression of bcl-2 and p53 in relation to clinicopathological features and estrogen receptor (ER) status in breast carcinomas from a series of 67 women who were treated surgically. Fifty and 23 cases showed positive immunostaining for bcl-2 and p53 protein, respectively. Thirty-five cases were ER-positive. A positive relationship was observed between bcl-2 and ER (p<0.05). Furthermore, an inverse relationship was observed between bcl-2 and p53 (p<0.01), which suggests that overexpression of p53 may down-regulate bcl-2 expression in breast carcinoma tissue, as has been described in a breast carcinoma cell line.     

胃粘膜异型增生和胃癌中Survivin基因的表达及相关性研究

目的 :探讨凋亡相关基因survivin在胃癌和胃粘膜异型增生组织中的表达 ,及其与bcl 2、p53和PCNA表达的相关性。方法 :利用免疫组织化学SP法检测 60例胃癌、3 0例胃粘膜异型增生和 8例正常胃粘膜中survivin、bcl 2、p53和PCNA的表达。 结果 :survivin在轻中重度异型增生和癌组织中阳性表达率分别是 10 %、13 %、80 %和 82 %。轻中重度异型增生survivin阳性表达率明显低于重度异型增生和癌 (P <0 0 1)而在重度异型增生与癌间无显著性差异 (P >0 0 5)。survivin阳性表达与胃癌组织学类型无关 (P >0 0 5) ,与浸润深度、淋巴结转移和生存期关系密切 (P <0 0 1、P <0 0 1、P <0 0 5)。survivin表达与bcl 2、p53和PCNAⅢ～Ⅳ级呈正相关 (P <0 0 1)。结论 :survivin基因在胃癌的发生、发展中起重要作用 ,检测survivin基因蛋白可对胃癌预后分析和进一步治疗提供有效依据 ,survivin与bcl 2和 p53一样可作为判断肿瘤预后的指标     

Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice

Epigallocatechin gallate (EGCG) is a major water-soluble component of green tea. The antimutagenic activity of EGCG against benzo[a]pyrene (B[a]P)-induced mutations was assessed by using transgenic mice carrying the rpsL gene as a monitor of mutations. Seven-week-old male mice were given drinking water containing EGCG for 3 weeks. On day 7, mice were treated with a single i.p. injection of B[a]P (500 mg/kg body wt). Two weeks after the injection, the mutations in the rpsL gene were analyzed. B[a]P treatment resulted in an approximately 4-fold increase of mutation frequency at the rpsL gene in the lung. An approximately 60% reduction in the B[a]P-induced mutations in the lung was observed when mice were given EGCG at concentrations >0.005%. B[a]P-induced mutations mainly occurred at G:C basepairs in the several specific nucleotide sequences of the rpsL gene. These were AGG, CGG, CGT, TGG, TGC and GGT: all of them contained a guanine residue. Mutations seen similarly in the human Ki-ras codon 12 or p53 codons 157, 248, and 273 of lung tumor were also found in the rpsL gene, and the mutations were suppressed by the EGCG treatment. In conclusion, the antimutagenic effects of EGCG for B[a]P-induced mutagenesis in vivo suggest that drinking green tea may reduce the tumor-initiating potency of B[a]P in the lung.     

PTEN及bcl-2和p53蛋白表达与乳腺癌预后的关系

目的 :探讨新的抑癌基因PTEN在人乳腺癌组织中的表达、与bcl 2、p5 3的相关性及其与乳腺癌临床病理学特征和预后的关系。方法 :采用免疫组化SP法检测62例浸润性乳腺癌 (包括浸润性导管癌、浸润性小叶癌、髓样癌等 )标本中PTEN、bcl 2及p5 3蛋白的表达。结果 :62例乳腺癌标本中PTEN、bcl 2及p5 3阳性表达率分别为 64 5 % ( 4 0 /62 )、5 6 5 % ( 3 5 /62 )及2 7 4% ( 17/62 ) ;PTEN与bcl 2之间不具有相关性 ,P >0 0 5 ;PTEN与p5 3之间显著相关 ,P <0 0 1。乳腺癌PTEN蛋白表达水平与患者年龄、肿瘤组织学类型、肿瘤大小之间差异无统计学意义 ,P >0 0 5 ;与肿瘤细胞学分级、淋巴结有无转移及预后之间差异有统计学意义 ,P <0 0 5 ;PTEN低表达患者肿瘤细胞学分级高、淋巴结转移阳性率高、5年生存率低。结论 :1)抑癌基因PTEN在乳腺癌中确实存在突变或缺失。其表达水平的高低作为判断乳腺肿瘤细胞增殖活性、侵袭力及转移的重要指标。 2 )PTEN与bcl 2协同表达与预后相关 ,可作为乳腺癌预后评估的有效指标。 3 )PTEN突变或缺失可能与p5 3存在一定的相关性 ,但其作用机制有待进一步研究。     

不同分化程度喉癌组织中bcl-2和p53的表达及其相互关系

目的 :探讨喉癌中抗凋亡基因bcl 2和突变型 p5 3的表达、相互关系及在喉癌发生机制中的作用。方法 :用免疫组化法对正常喉组织 2 7例和喉良性肿瘤 11例进行突变型 p5 3的检测 ,对喉癌 5 2例标本进行bcl 2与突变型p5 3的检测。结果 :正常喉组织突变型 p5 3免疫组化阳性检出率为 14 8% ( 4 /2 7) ,喉良性肿瘤为 18 2 % ( 2 /11) ,喉癌为61 5 % ( 3 2 /5 2 ) ,三者间差异有统计学意义 ,P <0 0 5 ;其中低分化喉鳞癌阳性检出率为 84 6% ,中分化为 73 0 % ,高分化为 15 4% ,三者间差异有统计学意义 ,P <0 0 5 ;低分化喉鳞癌bcl 2免疫组化阳性检出率为 69 2 % ( 9/13 ) ,中分化为 3 8 5 % ( 10 /2 6) ,高分化为 2 3 1%( 3 /13 ) ,三者间差异无统计学意义 ,0 1>P >0 0 5 ;喉癌中 p5 3的表达与bcl 2的表达呈明显正相关 ,0 0 2 >P >0 0 1。结论 :p5 3基因突变可作为喉部良性肿瘤向恶性转化及恶性程度增高的一个标志 ,在喉癌的发生机制上抑制细胞凋亡的bcl 2与 p5 3基因有协同作用     

Effect of green tea on p53 mutation distribution in ultraviolet B radiation-induced mouse skin tumors

In the present study, administration of green tea to SKH-1 mice, via the drinking fluid, was found to significantly reduce the incidence and volume of ultraviolet B (UVB) radiation-induced skin tumors. Thirty-six skin tumors induced by UVB and 32 skin tumors induced by UVB, in mice treated with green tea in their drinking water, were collected and examined for the presence of mutations in the p53 gene. Polymerase chain reaction products from p53 exons 5-8 were screened by single- strand conformation polymorphism and direct sequence analyses. Eight of 36 UVB-induced tumors contained nine p53 mutations, with four in exon 5 and five in exon 8. In contrast, nine of 32 UVB-induced tumors in mice treated with green tea contained 11 p53 mutations, with two in exon 5, five in exon 6 and four in exon 8. All of the p53 mutations occurred at dipyrimidine sequences. These results were further corroborated by p53 immunohistochemistry. The most frequent mutations were C-->T or T-->C transitions, which are consistent with the genetic alterations caused by UVB exposure. Interestingly, mutations found in exon 6 of the p53 gene occurred only in tumors from the UVB/green tea group. Thus, the tumors observed in UVB/green-tea-treated mice have a different exon distribution of p53 mutations than tumors obtained from mice treated with UVB alone.      

消化道多原发癌组织中凋亡相关蛋白p53和bcl-2的表达

目的研究消化道多原发癌组织中的p53和bcl-2蛋白表达状况，探讨p53和bcl-2基因在多原发癌的发生发展中的意义。方法应用免疫组织化学方法检测17例消化道双原发癌组织中的p53和bcl-2蛋白表达。结果17例患者34个独立癌灶中p53阳性者21个(21／34)，bcl-2阳性者14个(14／34)。3例患者第一癌和第二癌的p53和bcl-2表达均为阴性，其它14例患者第一癌和第二癌则有p53或／和bcl-2表达；5例患者p53和bcl-2在第一癌和第二癌中的结果一致，其它12例患者则有不同程度的区别。结论p53和bcl-2基因在消化道多原发癌的发生发展中可能起重要作用，对这些发现的意义值得进一步研究。     

bcl-2、p53在皮肤肿瘤中的表达及意义

目的探讨bcl-2、p53在几种皮肤肿瘤中的表达及意义。方法采用流式细胞术(FCM)和免疫荧光技术对皮肤鳞状细胞癌(SCC)、恶性黑色素瘤(MM)、基底细胞癌(BCC)、色素痣(PN)bcl-2、p53蛋白的表达进行定量分析,以荧光指数(FI)作为定量表达指标。结果鳞状细胞癌、基底细胞癌的bcl-2、p53基因蛋白的FI值均显著性高于正常对照(P<0.05),基底细胞癌的bcl-2基因的FI值显著性高于鳞状细胞癌(P<0.05),而二者的p53基因蛋白的FI值无显著性差异(P>0.05);恶性黑色素瘤、色素痣的bcl-2、p53基因蛋白的FI值均显著性高于正常对照(P<0.05),恶性黑色素瘤的p53基因的FI值显著性高于色素痣(P<0.05),而二者的bcl-2基因蛋白的FI值无显著性差异(P>0.05)。结论鳞状细胞癌、恶性黑色素瘤、基底细胞癌、色素痣中均有bcl-2的表达,基底细胞癌bcl-2表达显著高于鳞状细胞癌,说明基底细胞癌的发生发展可能与细胞凋亡受抑密切相关;p53在恶性黑色素瘤的表达高于色素痣,说明p53为黑色素瘤的恶性标志,检测p53表达可以作为鉴别皮肤黑色素瘤恶性病变的辅助手段。     

放疗前后宫颈癌细胞凋亡及Fas、p53及bcl-2的表达

目的:探讨Fas、p53及bcl-2放疗前后的变化及与细胞凋亡的关系。方法:采用免疫组织化学SP法和脱氧核糖核酸转移酶介导的缺口末端标记(TUNEL)技术,分别检测40例宫颈鳞癌患者放疗前后同一位点凋亡阳性率及Fas、p53和bcl-2的表达。结果:放疗前后凋亡阳性率有显著性差异(P<0.01);放疗后Fas与p53表达明显升高(P<0.01),而bcl-2表达明显降低(P<0.01);放疗后p53与Fas及bcl-2表达有相关性(P<0.05)。结论:Fas、p53及bcl-2对放射线诱导的宫颈癌细胞凋亡均具有重要调控作用。p53可能通过上调Fas在宫颈癌中的表达参与了放疗诱导的细胞凋亡过程。     

Expression of apoptosis-related proteins (p53, p21WAF1, bcl-2, and bax) and sensitivity to chemotherapy in squamous cell carcinoma of the esophagus

Background. Chemotherapy is an important component of the multimodal approach to the treatment of advanced esophageal squamous cell carcinoma. Methods. We investigated the associations between p53, p21 (Waf1), bcl-2, and bax expression and response to chemotherapy (cisplatin + 5-fluorouracil + leucovorin) in 43 patients with advanced esophageal squamous cell carcinoma. The expression of p53, p21 (Waf1), bcl-2, and bax proteins was analyzed immunohistologically in pretreatment biopsy and post-treatment resected specimens. Results. The 23 patients who had objective evidence of either a complete response (CR) or a partial response (PR) to chemotherapy survived for significantly longer than the 20 patients who had no response (NR). The expression of p53, p21 (Waf1), bcl-2, and bax was detected in 26 (61%), 12 (28%), 6 (14%), and 19 (44%) of the pretreatment biopsy specimens, respectively. The response to chemotherapy was not independently associated with the expression of any of these proteins. However, in the 26 patients with p53-expressing tumors, the response rate was 80% in patients whose tumor also expressed p21, whereas it was 19% in those whose tumor did not coexpress p21. No change in p53 expression was observed before and after chemotherapy, except in 1 patient; however, p21 expression appeared to be induced by chemotherapy in 5 patients. Patient survival was also not independently associated with the expression of any of these proteins. However, patients with p53-negative or p21-positive tumors had a better response to chemotherapy and survived for longer than those with p53-positive and p21-negative tumors. Conclusion. p53 and p21 expression in biopsy specimens obtained before chemotherapy could be useful predictors of response and survival in patients with advanced esophageal squamous cell carcinoma. Received: April 14, 1999 / Accepted: November 8, 1999     

多药耐药基因与细胞凋亡基因产物在非小细胞肺癌中的表达及其意义

 目的　检测非小细胞肺癌 (NSCLC)多药耐药相关基因及细胞凋亡基因的表达 ,探讨其表达的相关性及临床病理意义。方法　采用SP免疫组化法检测 113例NSCLC中多药耐药相关蛋白 (MRP)、谷胱甘肽巯基转移酶π(GST π)、肺耐药相关蛋白 (LRP)、突变型 p5 3和bcl 2的表达。 结果　NSCLC中MRP、GST π、LRP、p5 3和bcl 2的检出率分别为79.6 5 %、75 .2 2 %、80 .5 3%、6 1.95 %、5 9.2 9%。MRP、LRP和bcl 2的表达与组织学类型有关 (P <0 .0 5 )。p5 3与肿瘤细胞的分化程度有关 (P <0 .0 5 ) ,随着肿瘤细胞分化的恶性程度增加呈递增趋势。MRP与GST π、LRP表达之间 ,p5 3和bcl 2表达之间相关性有统计学意义 (P <0 .0 5 )。结论　不同组织学类型NSCLC的多药耐药性各不相同 ,且其耐药性之间还存在一定的相关性。检测NSCLC的多药耐药性有助于指导肺癌的化疗。     

细胞凋亡调节基因bcl-2、p53在卵巢浆液性囊腺癌中的表达及其与临床病理特征的关系

目的　探讨细胞凋亡调节基因bcl -2、p5 3在卵巢浆液性囊腺癌中的表达 ,以及这种表达与临床指标、生物学行为之间的关系。方法　用免疫组化S -P法检测bcl-2、p5 3在肿瘤组织中的表达。结果　肿瘤原发灶和相应淋巴结中 ,bcl -2、p5 3表达与淋巴结转移、临床分期、组织学分期有一定关系。结论　bcl -2、p5 3在卵巢浆液性囊腺癌的发展中起重要作用 ,对这两种基因的共同检测具有一定临床价值     

Survivin在非小细胞肺癌中的表达及其与bcl-2、p53表达的关系

目的　探讨Survivin在非小细胞肺癌组织 (non smallcelllungcancer ,NSCLC)中的表达 ,及其与bcl 2、p5 3蛋白表达的相关性。方法　应用免疫组织化学SP法 ,检测Survivin、bcl 2、p5 3蛋白在 5 7例NSCLC组织和 10例正常肺组织中的表达。结果　Survivin蛋白在正常肺组织中不表达 ,5 7例NSCLC组织中 ,3 4例表达阳性 ,占 5 9.6%。Survivin蛋白表达与分化程度、淋巴结转移密切相关 (P<0 .0 5 )。NSCLC组织bcl 2蛋白表达阳性、阴性组中 ,Survivin蛋白阳性表达率分别为 78.9%( 15 / 19)和 5 0 %( 19/ 3 8) ,两者比较 ,差异有显著性 (P <0 .0 5 ) ;p5 3蛋白表达阳性、阴性组中 ,Survivin蛋白阳性表达率分别为 72 .2 %( 2 6/ 3 6)和 3 8.1%( 8/ 2 1) ,两者比较 ,差异有显著性 (P <0 .0 5 ) ,Survivin蛋白表达与bcl 2、p5 3蛋白表达密切相关。结论　Survivin在NSCLC组织中表达上调 ,通过抑制细胞凋亡 ,在NSCLC的发生和发展中起到重要作用 ;凋亡相关基因bcl 2的上调和抑癌基因p5 3的失活与Survivin的表达可能在NSCLC癌变中起协同作用